Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases

Abstract

The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes

1 . A pharmaceutical composition for the treatment of obesity comprising an active ingredient, a mimic, derivative, or fragment thereof, which acts as an antagonist or inverse agonist of cannabinoid type 1 receptor and a pharmaceutically acceptable vehicle, characterized by the fact that administration of said pharmaceutical composition reduces body fat. 
     
     
         2 . A pharmaceutical composition according to  claim 1 , characterized by the fact that said reduction of body fat content does not cause collateral effects of depression. 
     
     
         3 . A pharmaceutical composition according to  claim 1  or  2 , characterized by the fact that said reduction in body fat content occurs in retroperitoneal, periepididymal and visceral adipose tissues. 
     
     
         4 . A pharmaceutical composition according to  claim 1 ,  2  or  3 , characterized by the fact that said reduction in body fat content can be localized to retroperitoneal tissues. 
     
     
         5 . A pharmaceutical composition according to  claim 1 ,  2  or  3 , characterized by the fact that said reduction in body fat content can be localized to periepididymal tissues. 
     
     
         6 . A pharmaceutical composition according to  claim 1 ,  2  or  3 , characterized by the fact that said reduction in body fat content can be localized to visceral adipose tissues. 
     
     
         7 . A pharmaceutical composition for preventing and treating diabetes comprising an active ingredient, a mimic, derivative, or fragment thereof, which acts as an antagonist or inverse agonist of cannabinoid type 1 receptor and a pharmaceutically acceptable vehicle, characterized by the fact that administration of said pharmaceutical composition improves insulin sensitivity. 
     
     
         8 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that said active ingredient is the peptide hemopressin, defined by the amino acid sequence proline-valine-asparagine-phenylalanine-lysine-phenylalanine-leucine-serine-histidine. 
     
     
         9 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that the two phenylalanines of the hemopressin peptide sequence are replaced by any two hydrophobic and aromatic groups. 
     
     
         10 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that the leucine portion of the hemopressin peptide sequence is replaced by any hydrophobic group. 
     
     
         11 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that said pharmaceutical composition may be administered intraperitoneally, intrathecally, or orally. 
     
     
         12 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that said active ingredient, mimic, derivative or fragment thereof, be administered in a dose varying from 0.05 micrograms per kilogram of body weight to 1 milligram per kilogram of body weight. 
     
     
         13 . A pharmaceutical composition according to  claim 1  or  7 , characterized by the fact that said active ingredient, mimic, derivative or fragment thereof, be administered in a dose varying from 0.05 micrograms per kilogram of body weight to 50 micrograms per kilogram of body weight. 
     
     
         14 . A pharmaceutical composition as in  claim 1  or  7 , characterized by the fact that the pharmaceutically acceptable vehicle is a sterile isosmotic solution. 
     
     
         15 . A pharmaceutical composition as in  claim 1  or  7 , characterized by the fact that the pharmaceutically acceptable vehicle is a sterile isosmotic solution with the same osmotic pressure of an isotonic solution of blood.